SAUHY (Straumann Holding AG) EBITDA Margin % : 38.42% (As of Jun. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Straumann Holding AG EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Straumann Holding AG's EBITDA for the six months ended in Jun. 2024 was $547 Mil. Straumann Holding AG's Revenue for the six months ended in Jun. 2024 was $1,425 Mil. Therefore, Straumann Holding AG's EBITDA margin for the quarter that ended in Jun. 2024 was 38.42%.

Straumann Holding AG EBITDA Margin % Historical Data

The historical data trend for Straumann Holding AG's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Straumann Holding AG EBITDA Margin % Chart

Straumann Holding AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

29.86

16.06

29.56

29.23

20.49

Straumann Holding AG Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBITDA Margin %	Get a 7-Day Free Trial															37.44	20.76	35.56	6.89	38.42

Competitive Comparison of Straumann Holding AG's EBITDA Margin %

For the Medical Instruments & Supplies subindustry, Straumann Holding AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Straumann Holding AG's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Straumann Holding AG's EBITDA Margin % falls into.

Straumann Holding AG EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Straumann Holding AG's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	571.429	/	2788.875
	=	20.49 %

Straumann Holding AG's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	547.322	/	1424.516
	=	38.42 %

Straumann Holding AG (OTCPK:SAUHY) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Straumann Holding AG EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Straumann Holding AG's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Straumann Holding AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Straumann Holding AG (OTCPK:SAUHY) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

SAUHF:USA STMNz:UK 0QMV:UK QS50:Germany STMN:Switzerland

Address

Peter Merian-Weg 12, Basel, CHE, 4002

Website

https://www.straumann-group.com

Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The company's core products are dental implants, and it holds roughly one third of the global implant dentistry market, which is estimated to be worth roughly CHF 5.4 billion. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.